

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 3

Complete If Known	
Application Number	10/568,292
Filing Date	August 14, 2006
First Named Inventor	Benny Bang-Andersen
Art Unit	1624
Examiner Name	N/A
Attorney Docket Number	463-US-PCT

U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature	/Emily Bernhardt/	Date Considered	05/09/2008
-----------------------	-------------------	--------------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>2</sup> Applicant's unique citation designation number (optional).<sup>3</sup> See Kinds Codes of USPTO Patent documents at [www.uspto.gov](http://www.uspto.gov) or MPEP § 601.04.<sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.<sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/568,292
Filing Date	August 14, 2006
First Named Inventor	Benny Bang-Andersen
Art Unit	1624
Examiner Name	N/A

Sheet

2

of

3

Attorney Docket Number 463-US-PCT

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/E.B./	5	BALSARA, J.J., et al. Effect of Drugs Influencing Central Serotonergic Mechanisms on Haloperidol-Induced Cataplexy. Psychopharmacol. 1972. 62:67-69.	
	6	BERTZ, R.J., et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clin. Pharmacokinet. 1997. 32(3):210-258.	
	7	CARLSSON, A. Antipsychotic Drugs, Neurotransmitters, and Schizophrenia. Am. J. Psych. 1978. 135(2):164-173.	
	8	CARLSSON, L., et al. QTU-Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and Interventions. J. Cardiovasc. Pharmacol. 1990. 16:276-285.	
	9	CHAURET, N., et al. The Use of 3-[2-(N,N-Diethyl-N-Methylammonium)Ethyl]-7-Methoxy-4-Methylcoumarin (AMMC) as a Specific CYP2D6 Probe in Human Liver Microsomes. Drug Metab. Dispos. 2001. 29(9):1196-1200.	
	10	CLARK, W.M., et al. A Highly Enantioselective Conjugate Reduction of 3-Arylinden-1-ones Using Bakers' Yeast for the Preparation of (S)-3-Arylinden-1-ones. Org. Lett. 1999. 1(11):1839-1842.	
	11	CLARK, W.M., et al. A Catalytic Enantioselective Synthesis of the Endothelin Receptor Antagonists SB-209670 and SB-217242: A Base-Catalyzed Stereospecific Formal 1,3-Hydrogen Transfer of a Chiral 3-Arylindanol. J. Am. Chem. Soc. 1998. 120:4550-4551.	
	12	COSSY, J., et al. Synthesis of Indatraline Using a Suzuki Cross-Coupling Reaction and a Chemoselective Hydrogenation: A Versatile Approach. Synlett. 2003. 10:1515-1517.	
	13	DARPÓ, B. Spectrum of Drugs Prolonging QT Interval and the Incidence of Torsades de Pointes. Eur. Heart J. Suppl. 2001. 3 Suppl. K:K70-K80.	
↓	14	ERESHEFSKY, L., et al. Serotonin Selective Reuptake Inhibitor Drug Interactions and the Cytochrome P450 System. J. Clin. Psych. 1996. 57(Suppl. 8):17-25.	

Examiner Signature	/Emily Bernhardt/	Date Considered	05/09/2008
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<i>Complete if Known</i>		
		Application Number	10/568,292	
		Filing Date	August 14, 2006	
		First Named Inventor	Benny Bang-Andersen	
		Art Unit	1624	
		Examiner Name	N/A	
Sheet	3	of	3	Attorney Docket Number
463-US-PCT				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/E.B./	15	GLASSMAN, A. H. et al. Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death. Am J Psychiatry. 2001. 158(11):1774-1782.		T <sup>2</sup>
	16	GU, X. H. et al. Design, Synthesis, and Monoamine Transporter Binding Site Affinities of Methoxy Derivatives of Indatraline. J. Med. Chem. 2000. 43:4868-4876.		
	17	HYTTEL, J. et al. Neurochemical Profile of Lu 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin. J. Neurochem. 1985. 44:1615-1622.		
	18	LIN, J. H. et al. Role of Pharmacokinetics and Metabolism in Drug Discovery and Development. Pharmacological Reviews. 1997. 49(4):403-449.		
	19	RAEHL, C. L. et al. Drug-induced torsade de pointes. Clin. Pharm. 1985. 4:675-690.		
	20	RENDIC, S. et al. Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors. Drug Metab. Rev. 1997. 29(1&2):413-580.		
	21	SCHULMAN, R.W. et al. Psychotropic Medications and Cytochrome P450 2D6: Pharmacokinetic Considerations in the Elderly. Can. J. Psych. 1997. 42(suppl 1):S-9S.		
	22	WOOSLEY, R. L. Cardiac Actions of Antihistamines. Ann. Rev. Pharmacol. Toxicol. 1996. 36:233-252.		
	23	YAP, Y.G. et al. The current cardiac safety situation with antihistamines. Clin. Exper. Allergy. 1999. 29 (suppl 1):15-24.		
↓	24	YUN, J. et al. Efficient Kinetic Resolution in the Asymmetric Hydrosilylation of Imines of 3-Substituted Indanones and 4-Substituted Tetralones. J. Org. Chem. 2000. 65:767-774.		

Examiner Signature	/Emily Bernhardt/	Date Considered	05/09/2008
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This form or information is required by 37 CFR 1.98. The burden of proof is upon the applicant to show what benefit he or she obtained or retained by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.